Amyloidosis

Patients beginning lung cancer treatment demonstrated a high prevalence of atherosclerosis, which suggests that they may benefit from calcium scoring, new data showed.

Healio spoke with Chakra Chaulagain, MD, about phase 3 PERSEUS trial results presented at ASH 2023.

The FDA rejected a supplemental new drug application for patisiran to treat cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, citing insufficient evidence of clinical meaningfulness.

An FDA panel voted 9-3 in favor of expanding approval of patisiran to patients with cardiomyopathy of wild-type transthyretin-mediated or hereditary transthyretin-mediated amyloidosis, noting modest benefits but no significant safety concerns.

PHILADELPHIA — In this Healio video exclusive, Yehuda Handelsman, MD, FACP, FNLA, FASCP, MACE, co-chair of the Heart in Diabetes CME Conference, discusses the mission and purpose of the meeting.

NEW ORLEANS — Black female carriers of the V122I genetic variant for cardiac amyloidosis have substantially higher CVD and all-cause mortality risk, which grows with age, compared with noncarriers, researchers reported.

A new expert consensus decision pathway published by the American College of Cardiology highlights the importance of recognizing and diagnosing cardiac amyloidosis at an early stage to allow the most favorable outcome.